The Institute of Molecular and Cell Biology (IMCB) was established in 1987 at the National University of Singapore (NUS) before becoming an autonomous research institute (RI) of A*STAR and moving to Biopolis in 2004. Its mission is to develop and foster a vibrant research culture for cutting-edge biomedical sciences and for training high-quality Ph.D. students for the flourishing biotechnology and pharmaceutical industries in Singapore.
Funded primarily by the Biomedical Research Council (BMRC) of A*STAR, IMCB’s research activities focus on four major fields: Animal Models of Development and Disease, Cancer Genetics and Therapeutics, Cell Biology in Health and Disease, and Structural Biology and Drug Discovery.
IMCB was awarded the Nikkei Prize 2000 for Technological Innovation in recognition of its growth into a leading international research centre and its collaboration with industry and research institutes worldwide. Sixteen IMCB Principal Investigators have received National Science and Technology Awards and Medals. The Institute continues to publish in renowned international journals and has more than 2,000 publications to its credit since 1987. IMCB has also trained more than 220 postgraduate students.
IMCB has numerous collaborations with industrial, translational clinical and academic partners both in Singapore and worldwide. Recent highlights include the licensing of DNA methylation technology to Hitachi Asia Ltd. for cancer diagnostics development, the collaboration with Merlion Pharmaceuticals for a drug discovery program, licensing of zebrafish (Danio rerio) genetic markers, licensing of microbial collections for drug screening, development of SARS and malaria diagnostic kits and licensing of several monoclonal antibodies.
IMCB strives to maintain the scientific excellence of PI-driven research and at the same time aims to promote collaborative team-based projects of medical and industrial relevance.